TransMedics Group (NASDAQ:TMDX) Earns Overweight Rating from Piper Sandler

Piper Sandler restated their overweight rating on shares of TransMedics Group (NASDAQ:TMDX) in a report issued on Wednesday morning, Benzinga reports. Piper Sandler currently has a $120.00 target price on the stock, up from their prior target price of $95.00.

Other analysts also recently issued research reports about the company. Morgan Stanley boosted their price objective on TransMedics Group from $75.00 to $95.00 and gave the company an equal weight rating in a research report on Wednesday, February 28th. JPMorgan Chase & Co. upped their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the company an overweight rating in a report on Tuesday, February 27th. Finally, Oppenheimer raised their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an outperform rating in a report on Wednesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $119.00.

TransMedics Group Price Performance

TMDX stock opened at $127.99 on Wednesday. The firm has a market cap of $4.19 billion, a P/E ratio of -376.44 and a beta of 1.87. The firm’s fifty day moving average is $85.54 and its 200 day moving average is $76.85. TransMedics Group has a 52 week low of $36.42 and a 52 week high of $129.66. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.40. The business had revenue of $96.90 million during the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The company’s revenue was up 132.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.08) earnings per share. Research analysts predict that TransMedics Group will post -0.14 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the sale, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at approximately $7,044,932.83. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CEO Waleed H. Hassanein sold 12,000 shares of the stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James R. Tobin sold 15,040 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $106.43, for a total transaction of $1,600,707.20. Following the completion of the sale, the director now owns 205,171 shares of the company’s stock, valued at $21,836,349.53. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 236,378 shares of company stock valued at $23,633,449. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently made changes to their positions in the company. J.W. Cole Advisors Inc. purchased a new position in TransMedics Group during the third quarter valued at $929,000. Bank of New York Mellon Corp lifted its position in TransMedics Group by 91.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after acquiring an additional 363,012 shares during the period. Shariaportfolio Inc. purchased a new position in TransMedics Group during the 3rd quarter valued at about $470,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in TransMedics Group by 12.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,913 shares of the company’s stock worth $378,000 after acquiring an additional 763 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in TransMedics Group by 12.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,940 shares of the company’s stock worth $818,000 after purchasing an additional 1,700 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.